Valerio Therapeutics (XPAR:ALVIO) ROCE % : -61.23% (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Valerio Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Valerio Therapeutics's annualized ROCE % for the quarter that ended in Dec. 2023 was -61.23%.

Valerio Therapeutics ROCE % Historical Data

The historical data trend for Valerio Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valerio Therapeutics ROCE % Chart

Valerio Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-81.16

7.81

-11.54

-41.70

-67.20

Valerio Therapeutics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial															-2.51	-40.74	-38.75	-68.37	-61.23

Valerio Therapeutics ROCE % Calculation

Valerio Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-20.187	/	( ( (43.086 - 7.149)	+	(35.274 - 11.13) )	/ 2 )
	=	-20.187	/	( (35.937	+	24.144)	/ 2 )
	=	-20.187	/	30.0405
	=	-67.20 %

Valerio Therapeutics's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-17.17	/	( ( (44.02 - 12.082)	+	(35.274 - 11.13) )	/ 2 )
	=	-17.17	/	( ( 31.938	+	24.144 )	/ 2 )
	=	-17.17	/	28.041
	=	-61.23 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Valerio Therapeutics (XPAR:ALVIO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Valerio Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Valerio Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Valerio Therapeutics (XPAR:ALVIO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valerio Therapeutics (XPAR:ALVIO) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

C4X:Germany

Address

49 Boulevard du General, Martial Valin, Paris, FRA, 75015

Website

https://www.valeriotx.com

Valerio Therapeutics is a clinical-stage biotechnology company designing and developing novel oncology drugs targeting tumor DNA repair functions. Its therapeutic strategy focuses on fighting tumor resistance to treatments, which poses ever-greater therapeutic challenges, especially in aggressive or rare cancers. its approach is based upon unique mechanisms of action on DNA Damage Response. The company focuses on bringing first-in-class and disruptive compounds from preclinical research to proof-of-concept in man in cancer indications with high unmet needs.

Valerio Therapeutics (XPAR:ALVIO) Headlines

No Headlines